Cases & Deals

  • Home
  • Practices
  • Celldex Therapeutics develops worldwide patent portfolios for anti-tyrosine kinase receptor therapeutic antibodies

Share

Celldex Therapeutics develops worldwide patent portfolios for anti-tyrosine kinase receptor therapeutic antibodies

May 2017

Client(s) Celldex Therapeutics, Inc.

Jones Day is representing Celldex Therapeutics, Inc. in connection with the development and prosecution of global portfolios related to the company's lead clinical and pre-clinical anti-tyrosine kinase receptor therapeutic antibodies.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.